Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.58 |
| ▸ | DAO | P14920 | 3/20 | 0.51 |
| ▸ | PARP1 | P09874 | 3/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | CLK2 | P49760 | 1/20 | 0.36 |
| ▸ | CLK3 | P49761 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 4/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30300382 | 0.84 | DAO (0.51) | PDE3BPDE3ADAOPARP1HRH4 | |
| Isoquinoline SCHEMBL28494168 | 0.83 | PDE3B (0.49) | PDE3BPDE3ADAOPARP1ACHE | |
| Pyrazine SCHEMBL28109443 | 0.77 | CA12 (0.42) | PDE3BPDE3ADAOPARP1 | |
| SCHEMBL10417 | 0.75 | CA12 (0.48) | PDE3BPDE3ADAOMAPT | |
| SCHEMBL28015378 | 0.75 | CA12 (0.48) | PDE3BPDE3ADAOMAPT | |
| SCHEMBL29371690 | 0.75 | CA12 (0.48) | PDE3BPDE3ADAOMAPT | |
| Pyridine SCHEMBL27907784 | 0.74 | CYP19A1 (0.41) | PDE3BPDE3ADAOMAPT | |
| SCHEMBL31540593 | 0.73 | CA12 (0.47) | PDE3BPDE3ADAOMAPT | |
| Bromide SCHEMBL5616601 | 0.73 | CA12 (0.47) | PDE3BPDE3ADAOMAPT | |
| SCHEMBL21358065 | 0.73 | CA12 (0.47) | PDE3BPDE3ADAOMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4069695-A1 | DERIVATIVES OF AN FGFR INHIBITOR | Incyte Corporation (US) | 2022-10-12 | — | — | EP | claimed |
| US-20240300948-A1 | Heterocyclic Compounds As Kinase Inhibitors | INCYTE CORPORATION | 2024-09-12 | — | — | US | disclosed |
| EP-4403216-A2 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | Incyte Holdings Corporation (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-3822273-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | INCYTE HOLDINGS CORP (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4323405-A1 | COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A NECTIN-4 TARGETING AGENT | Incyte Corporation (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2022221170-A1 | COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A NECTIN-4 TARGETING AGENT | INCYTE CORPORATION (US) | 2022-10-20 | — | — | WO | disclosed |
| CN-115151539-A | Derivatives of FGFR inhibitors | 因赛特公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-115023414-A | Compound for organic electric element, organic electric element using the same, and electronic device thereof | 德山新勒克斯有限公司 | 2022-09-06 | — | — | CN | disclosed |
| EP-2718293-B1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | HUTCHISON MEDIPHARMA LTD (CN) | 2017-10-25 | — | — | EP | disclosed |
| WO-2015057963-A1 | FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-23 | — | — | WO | disclosed |
| EP-2861595-A2 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | Incyte Corporation (US) | 2015-04-22 | — | — | EP | disclosed |
| WO-2014007951-A2 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2014-01-09 | — | — | WO | disclosed |
| WO-2012075562-A1 | MICROSPORE TRANSFORMATION METHODOLOGY BY MACROINJECTION | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2012-06-14 | — | — | WO | disclosed |
| US-6696565-B2 | SELF-ASSEMBLING; PHYSICAL PROPERTIES; THERMOCONDUCTIVITY | PURDUE RESEARCH FOUNDATION | 2004-02-24 | — | — | US | disclosed |
| US-6395733-B1 | ANTICANCER AGENTS; ANTIPROLIFERATIVE AGENTS | PFIZER INC | 2002-05-28 | — | — | US | disclosed |
| WO-1996040142-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300948-A1 | Heterocyclic Compounds As Kinase Inhibitors | JAK2, JAK1, JAK3 | PDE3B 2833/4885PDE3A 3233/4885DAO 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.